{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:37:21Z","timestamp":1777743441770,"version":"3.51.4"},"reference-count":20,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: The combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is a very effective chemotherapeutic regimen for unresectable pancreatic cancer. Previous studies have reported that female gender may be a predictor of a better response to FOLFIRINOX. This study was aimed at investigating the clinical outcomes and dose modification patterns of FOLFIRINOX by gender. Methods: Patients with metastatic pancreatic cancer (MPC) who began FOLFIRINOX as the first-line therapy at Seoul National University Bundang Hospital between 2013 and 2018 were enrolled. The patients received at least four chemotherapy cycles. Local regression and a linear mixed model were used to analyze dose modification patterns by gender. Results: Ninety-seven patients with MPC (54 men; 43 women) were enrolled. In the first FOLFIRINOX cycle, there were significant differences in age and body surface area between the genders (58.8 (men) and 64.9 years (women), p = 0.005; 1.7 (men) and 1.6 m2 (women), p &lt; 0.001, respectively). The median progression-free survival (PFS) and overall survival (OS) were 10.8 and 18.0 months, respectively. There was a trend of longer PFS (10.3 (men) and 11.9 months (women), p = 0.153) and a significantly longer OS (17.9 (men) and 25.9 months (women), p = 0.019) in female patients. During the first year of FOLFIRINOX treatment, there was a significant difference of the age-corrected dose reduction pattern by gender (a mean of 95.6% dose at the initial cycle and \u22120.35% of dose reduction per week in men versus a mean of 90.7% dose at the initial cycle and \u22120.53% of dose reduction per week in women, p-value of the slope: &lt;0.001). There was no difference in the adverse event rates between the genders. Conclusions: Female patients showed longer OS despite a more rapid dose reduction during each cycle. Gender differences should be considered during FOLFIRINOX treatment.<\/jats:p>","DOI":"10.3390\/jpm11020083","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T06:22:20Z","timestamp":1611987740000},"page":"83","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX"],"prefix":"10.3390","volume":"11","author":[{"given":"Jinkook","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunjeong","family":"Ji","sequence":"additional","affiliation":[{"name":"Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwangrok","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7107-3624","authenticated-orcid":false,"given":"Jaewoo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Chan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-7015","authenticated-orcid":false,"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hyeok","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-1415","authenticated-orcid":false,"given":"Jaihwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1758835919875568","DOI":"10.1177\/1758835919875568","article-title":"An update on treatment options for pancreatic adenocarcinoma","volume":"11","author":"Lambert","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4062\/biomolther.2018.103","article-title":"Sex Differences in Cancer: Epidemiology, Genetics and Therapy","volume":"26","author":"Kim","year":"2018","journal-title":"Biomol. Ther. (Seoul)"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3892\/ijo.2013.2176","article-title":"Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review","volume":"44","author":"Hohla","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lambert, A., Jarlier, M., Gourgou Bourgade, S., and Conroy, T. (2017). Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4\/ ACCORD 11 randomized trial. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183288"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","article-title":"Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity","volume":"76","author":"Lee","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","article-title":"The importance of dose intensity in chemotherapy of metastatic breast cancer","volume":"2","author":"Hryniuk","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/annonc\/mdz414","article-title":"Gender medicine and oncology: Report and consensus of an ESMO workshop","volume":"30","author":"Wagner","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","article-title":"Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: Results from a prospective population pharmacokinetic study","volume":"71","author":"Mueller","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jcph.543","article-title":"Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure","volume":"55","author":"Berg","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1067\/mcp.2002.129502","article-title":"Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide","volume":"72","author":"Klein","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00228-013-1580-y","article-title":"Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors","volume":"69","author":"Wu","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2018.1080","article-title":"Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group","volume":"4","author":"Cristina","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/2\/83\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:17:33Z","timestamp":1760159853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/2\/83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jpm11020083"],"URL":"https:\/\/doi.org\/10.3390\/jpm11020083","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,30]]}}}